ARRY-380 is an ErbB-2 inhibitor that selectively binds to and inhibits the phosphorylation of ErbB-2, resulting in growth inhibition and death of ErbB-2-expressing tumor cells.
More Information Supplier PageARRY-380 is an ErbB-2 inhibitor that selectively binds to and inhibits the phosphorylation of ErbB-2, resulting in growth inhibition and death of ErbB-2-expressing tumor cells.
More Information Supplier PageARRY-380 is an ErbB-2 inhibitor that selectively binds to and inhibits the phosphorylation of ErbB-2, resulting in growth inhibition and death of ErbB-2-expressing tumor cells.
More Information Supplier PageMK-4827 is a novel potent, orally bioavailable PARP-1 and PARP-2 inhibitor.
More Information Supplier PageMK-4827 is a novel potent, orally bioavailable PARP-1 and PARP-2 inhibitor.
More Information Supplier PageGeldanamycin binds to the ATP site of Hsp90 (Kd = 1.2 ??M) and inhibits its chaperone activity.
More Information Supplier PageGeldanamycin binds to the ATP site of Hsp90 (Kd = 1.2 ??M) and inhibits its chaperone activity.
More Information Supplier PageNVP-AEW541 is a selective IGF-1R kinase inhibitor that inhibits the autophosphorylation activity of IGF-1R (IC50 = 0.086 uM) and prevents IGF-1-mediated survival and proliferation of MCF-7 cells (IC50 = 0.16 and 1.64 uM, respectively).
More Information Supplier PagePCI-32765 is an orally bioavailable small-molecule inhibitor of Bruton’s tyrosine kinase (BTK) with potential antineoplastic activity.
More Information Supplier PagePCI-32765 is an orally bioavailable small-molecule inhibitor of Bruton’s tyrosine kinase (BTK) with potential antineoplastic activity.
More Information Supplier Page
